NCT00232050View on ClinicalTrials.gov

Study of Omalizumab in Moderate to Severe Bronchial Asthma

PHASE3CompletedINTERVENTIONAL
Enrollment

327

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

May 31, 2005

Study Completion Date

May 31, 2005

Conditions
Asthma
Interventions
DRUG

Omalizumab

Sponsors

Lead Sponsor

Novartis

Collaborators (1)

Daiichi Sankyo Co., Ltd.
All Listed Sponsors
collaborator

Daiichi Sankyo Co., Ltd.

INDUSTRY

lead

Novartis

INDUSTRY

NCT00232050 - Study of Omalizumab in Moderate to Severe Bronchial Asthma | Biotech Hunter | Biotech Hunter